Compare Goodyear Tire & Rubber Co (GT) vs Moderna, Inc. (MRNA) Price & Performance

Goodyear Tire & Rubber (GT) trades at $5.955, down 1.24% on the day, with a bearish technical signal and mixed analyst sentiment. The company reported a Q2 2026 loss of $0.61 per share, beating expectations but reflecting ongoing volume pressure. Revenue trends show a decline from $20.8B in 2022 to $17.7B projected for 2026, with negative net income margins. Valuation metrics appear attractive with P/E of 4.69 and P/B of 0.62, but profitability remains challenged with ROE at -63.93%.

The outlook remains cautious as Goodyear faces persistent volume declines and competitive pressures, though cash flow improvements and Asia Pacific gains provide some support. Investment opportunity exists in the deeply discounted valuation if operational turnaround succeeds, but risks include continued market share erosion and high debt levels. Analyst consensus shows 34.6% buy ratings with 50% recommending hold, indicating Wall Street's wait-and-see approach.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.